prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Advanced prostate cancer in combination w/ LHRH analogue therapy or surgical castration.

Indication: Palliative treatment of hormone-dependent advanced prostate cancer. High-risk localized & locally advanced...

Indication: Adult men w/ metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after ...

Indication: In combination w/ prednisone or prednisolone for the treatment of metastatic castration resistant prostate can...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carci...

Indication: Monotherapy or combination therapy for palliative treatment of metastatic non-seminomatous germ cell carcinoma...

Indication: Locally advanced or metastatic prostate cancer. Genital & extragenital stage I-IV endometriosis. Precociou...

Indication: Breast, gastric, ovarian & small cell lung cancer; non-Hodgkin's lymphoma; advanced/metastatic soft tissue...

1  /  6
Editor's Recommendations
Most Read Articles
3 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
6 days ago
Atrial fibrillation (AF) carries an excess risk of stroke recurrence independent of comorbidity with and heart failure (HF), while HF without AF also poses a significant risk of recurrence, a study has shown.
Roshini Claire Anthony, 2 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.